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Abstract
Background: Yellow fever (YF) is an acute viral hemorrhagic disease transmitted by Aedes mosquitoes. The causative agent,
the yellow fever virus (YFV), is found in tropical and subtropical areas of South America and Africa. Although a vaccine is
available since the 1930s, YF still causes thousands of deaths and several outbreaks have recently occurred in Africa.
Therefore, rapid and reliable diagnostic methods easy to perform in low-resources settings could have a major impact on
early detection of outbreaks and implementation of appropriate response strategies such as vaccination and/or vector
control.
Methodology: The aim of this study was to develop a YFV nucleic acid detection method applicable in outbreak
investigations and surveillance studies in low-resource and field settings. The method should be simple, robust, rapid and
reliable. Therefore, we adopted an isothermal approach and developed a recombinase polymerase amplification (RPA) assay
which can be performed with a small portable instrument and easy-to-use lyophilized reagents. The assay was developed in
three different formats (real-time with or without microfluidic semi-automated system and lateral-flow assay) to evaluate
their application for different purposes. Analytical specificity and sensitivity were evaluated with a wide panel of viruses and
serial dilutions of YFV RNA. Mosquito pools and spiked human plasma samples were also tested for assay validation. Finally,
real-time RPA in portable format was tested under field conditions in Senegal.
Conclusion/Significance: The assay was able to detect 20 different YFV strains and demonstrated no cross-reactions with
closely related viruses. The RPA assay proved to be a robust, portable method with a low detection limit (,21 genome
equivalent copies per reaction) and rapid processing time (,20 min). Results from real-time RPA field testing were
comparable to results obtained in the laboratory, thus confirming our method is suitable for YFV detection in low-resource
settings.
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Introduction
Yellow fever (YF) has been one of the most feared diseases
during the past centuries, its historical impact ranking next to
plague and smallpox. Unfortunately, unlike smallpox, YF virus
(YFV) cannot be eradicated as its transmission by mosquitoes
includes a sylvatic cycle. Despite the use of an effective vaccine
since the 1930s, the World Health Organization (WHO) estimates
that the disease affects more than 200,000 persons causing 30,000
deaths per year [1]. YF remains an important public health
problem for the populations of 44 countries, 33 in Africa and 11 in
Central and South America, where altogether almost 900 million
people are at risk. In recent years, the number of YF cases has
increased [2], and there is great concern that the disease might be
introduced into new areas [3]. Recently, severe outbreaks have
occurred in regions of Africa that have long been free of the virus,
such as Darfur in Sudan or South Omo in Ethiopia which
experienced the worst YF outbreak in Africa in 20 years in 2012
[4].
YFV is the prototype of the genus Flavivirus (family Flavivir-
idae) which comprises more than 80 positive-sense, single-stranded
RNA viruses, including other human pathogens such as dengue,
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West Nile virus, Usutu virus, Zika virus, Japanese encephalitis
virus and Tick-borne encephalitis virus [5].
Diagnosis of YFV infection is very challenging as the early
symptoms caused by YFV are not specific. Laboratory confirma-
tion is therefore essential for the differential diagnosis of YF with
leptospirosis, malaria, viral hepatitis and other hemorrhagic
diseases. Laboratory testing is also challenged by the short
duration of the YF viremia in humans, the low-level laboratory
infrastructure in most endemic areas and cross-reactions when
using serological methods which lack specificity [6–8].
Alternatively, molecular diagnostic methods represent essential
tools for early diagnostics as they are able to detect infections
during the viremic phase. Early detection of cases is crucial to
provide efficient patient management, rapid outbreak response
and emergency vaccination measures. For this reason, consider-
able efforts are made to develop accessible direct detection
methods based on molecular detection which allow a rapid and
highly sensitive detection of YFV. Several molecular methods for
YFV detection based on polymerase chain reaction (PCR), such as
real-time RT-PCR, have been established, but these methods
require the use of complex instruments and well-equipped
laboratories [9–13]. However, in the case of direct detection
methods for YFV, it is essential to be able to provide a portable,
simple and robust method suitable for low-resource settings and
field diagnosis, especially for outbreak response. For this reason,
new molecular methods based on isothermal amplification have
been developed for YFV detection, such as real-time reverse-
transcription loop-mediated isothermal amplification (RT-LAMP)
[14] and helicase-dependent amplification assays (HDA) [15].
In this study, we describe the establishment of a reverse-
transcriptase recombinase polymerase amplification (RPA) assay
for YFV detection. During RPA reaction, YFV RNA is first
transcripted to DNA by a reverse-transcriptase. Secondarily, a
phage derivated recombinase forms a nucleoprotein complex with
the oligonucleotide primers which is able to scan for homologous
sequences in the DNA template. RPA reaction can be performed
between 25 and 42uC since denaturation of the DNA template is
not required. If the target is present, the oligonucleotides are
extended by strand displacing polymerases [16]. Real-time signal
detection of the amplification can be performed within 15 minutes
by using TwistAmpTM Exo probes (TwistDx, Cambridge, UK) and
a ESEQuant Tube Scanner (QIAGEN Lake Constance GmbH,
Stockach, Germany), a small easy-to-use fluorescence detection
system which can perform eight measurements simultaneously. In
low-resource settings where no power supply is available, the Tube
Scanner device can be powered by a car adaptor, a small
rechargeable battery or a battery charged by solar panels [17].
The RPA assay can also be integrated into a semi-automated
system, using a GeneSlice microfluidic cartridge (HSG-IMIT,
Freiburg, Germany) installed in a ‘‘SONDE’’ player device. As an
alternative to real-time measurement, RPA results may be
visualized after amplification on lateral-flow stripes (LFS) by using
a different probe, TwistAmpTM Nfo (TwistDx, Cambridge, UK),
during the RPA reaction. The reaction system can be stabilized in a
dried formulation transportable without a cold chain.
Materials and Methods
Viruses and mosquito pools
Virus strains used were provided by the Robert Koch Institute
in Berlin, the Bernhard-Nocht-Institute in Hamburg in Germany,
and the Pasteur Institute of Dakar in Senegal. All virus strains were
derived from cell culture, inactivated and stabilized. YFV strains
are listed in Table 1 and other viral strains in Table 2.
Pools of mosquitoes, some of them infected with YFV, were
provided by the Pasteur Institute of Dakar. The mosquito sampling
protocol was extensively described by Diallo and colleagues [18].
RNA extraction and sample preparation
Viral RNA was isolated from 140-ml aliquots of cell culture
supernatants or 100-ml aliquots of mosquito pools, using the QIAamp
Viral Mini Kit (QIAGEN Lake Constance GmbH, Stockach,
Germany) according to the manufacturer’s instructions. RNA was
eluted in 100 ml of elution buffer and stored at 280uC until further use.
In order to use an energy-free method in the field trial, RNA
extraction was performed with the innuPREP MP Basic Kit A
(Jena Analytik, Jena, Germany) with a magnetic bead separation
rack combined with proteinase K treatment according to the
manufacturer’s instructions. The nucleic acids were eluted in
100 ml of nuclease-free distilled water, and 5 ml were subjected to
PCR or RPA, respectively.
RNA was extracted from 10-fold serial dilutions of YFV
preparation and stored in aliquots at 280uC until use to assess the
sensitivity of the extraction method. Human plasma samples
spiked with low concentrations of YFV were used as a model for
assay validation with clinical samples.
Primer and probe design for RPA
All of the 79 YFV full-length sequences covering the 59-UTR
region available in the database (NCBI) were aligned using
Geneious 5.0 software. According to Piepenburg and colleagues,
primers of 30 nt to 35 nt in length are recommended for RPA [16].
One set of degenerate generic primers (YFV RF/RR) was designed
according to the alignment for amplification of different YFV strains
(Table 1). The primer sequences were identical for both lateral-flow
strip RPA (LFS RT-RPA) and real-time RT-RPA primers, except
for an additional biotinylation at the 59 end of the LFS reverse
primer. RPA exo probe for fluorogenic detection and RPA nfo
probe for detection of dual-labeled amplicon were designed
according to RPA guidelines from TwistDx (Cambridge, United
Kingdom) and synthesized by TIB MOLBIOL (Berlin, Germany).
Real-time RT-PCR
YFV-specific primer YFV FP/RP and probe YFV LNA2 were
used to detect and quantify genomic RNA of YFV as described
previously [9]. The assay was performed in a one-step format on
the ABI 7500 instrument using the QuantiTect Virus Kit
(QIAGEN Lake Constance GmbH, Stockach, Germany).
Author Summary
Despite the use of a safe and effective vaccine, yellow
fever virus is still causing hundreds of thousands of
infections and tens of thousands of deaths every year. The
disease is widespread in South America and Africa where
several outbreaks have occurred in the past years. As the
disease is difficult to distinguish from other illnesses during
its early stage, it is necessary to develop reliable, rapid and
simple diagnostic methods to confirm YF cases to be able
to respond effectively to outbreaks through vaccination
and vector control. In this study, we describe the
development a diagnostic method for YFV, using an
isothermal technology called recombinase polymerase
amplification which allows detection of the virus within
20 minutes, using a portable and easy-to-use device. The
YFV RPA assay proved to be a specific and sensitive
detection method during testing in the laboratory and
under field conditions in Senegal.
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Lateral-flow strip RT-RPA assay
LFS-RPA assay was performed using the TwistAmpTM nfo RT
kit from TwistDx (Cambridge, United Kingdom) according to the
manufacturer’s instructions. Briefly, 29.5 ml of rehydration solu-
tion were mixed with 7.2 ml of PCR water, 2.1 ml of each primer
(10 mM) and 0.6 ml of the target-specific RPA nfo probe (10 mM).
Then 5 ml of RNA template was added to the 41.5 ml master mix.
The template/master mix solution was added to the dry reagent
pellet and mixed by pipetting up and down. Finally, the reaction
was triggered by adding 3.5 ml of magnesium acetate (Mg(OAc)2,
Table 1. Yellow fever viral strains used for analytical specificity testing.
Virus description Accession No. Origin Date Lineage
real-time RT-
PCR RT-RPA
YFV virus strains Ct values real-time Tt [min] LFS
ArD 24553 _ Senegal 1976 _ 24,6 3,3 n.d.
ArD 408/78 _ Burkina Faso 1978 _ 23,9 3,0 n.d.
HD 117294 JX898868 Senegal 1995 6 16,5 2,3 n.d.
ArD 114891 _ Senegal 1995 6 16,0 1,6 n.d.
ArD 99740 _ Senegal 1993 3 25,0 5,1 n.d.
ArD 114991 _ Senegal 1995 _ 24,3 3,4 n.d.
HD 122030 _ Senegal 1996 6 19,4 2,4 n.d.
ArD 122522 _ Senegal 1996 6 21,3 3,3 n.d.
HA 016/97 _ Liberia 1997 _ 20,0 1,6 n.d.
HD 47471 _ Mauritania 1987 _ 28,5 5,9 n.d.
ArD D X _ Senegal 2000 5 21,4 2,4 n.d.
Asibi AY640589.1 Ghana 1927 _ 20,6 3,2 pos
ArD 114896 JX898871 Senegal 1995 3 20,3 3,1 pos
ArD 156468 JX898876 Senegal 2001 4 16,8 2,4 pos
DakArAmt7 JX898869 Ivory Coast 1973 1 15,4 2,1 pos
ArD 121040 JX898870 Senegal 1996 6 16,4 2,3 pos
ArD 149214 JX898873 Senegal 2000 5 15,5 2,2 pos
Ivory C 1999 AY603338.1 Ivory Coast 1999 6 19,1 2,5 pos
Trinidad 79A 788379 AF094612.1 Brazil 1979 3 20,1 2,5 pos
17D RKI #142/94/1 Vaccine strain RKI _ _ 20,0 2,1 pos
n.d.: not determined; pos: positive; neg: negative; Tt: time threshold.
doi:10.1371/journal.pntd.0002730.t001
Table 2. Viral strains other than YFV used for analytical specificity testing.
Virus family Virus specie Virus strain Real-time RT-PCR RT-RPA result
reference result (Ct) real-time/LFS
Flaviviridae other than Dengue virus serotype 1 VR344 (Thai 1958 strain) 15.9 neg
YFV Dengue virus serotype 2 VR345 (TH-36 strain) [28] ih 18.8 neg
Dengue virus serotype 3 VR216 (H87 strain) 20.3 neg
Dengue virus serotype 4 VR217 (H241 strain) 16.2 neg
West Nile virus lineage 1 Israel [29] 19.9 neg
West Nile virus lineage 2 Uganda 26.8 neg
TB Encephalitis virus K23 strain [30] 16.3 neg
RSS Encephalitis virus Far eastern subtype 24.2 neg
Japanese Encephalitis virus ATCC SA14-14-2 [31] 19.4 neg
Bunyaviridae Rift Valley Fever virus strain ZH548 [32] 26.2 neg
Filoviridae Ebola virus Zaire strain [33] 24.7 neg
Marburg virus Musoke strain 24.4 neg
Alphaviridae Chikungunya virus African isolate ih 17.5 neg
TB: Tick-borne; RSS: Russian Spring Summer; neg: negative; ih: in-house assay.
doi:10.1371/journal.pntd.0002730.t002
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280 mM) to the 46.5 ml reaction mix. The reaction mix was placed
into the heating block at 39uC for 20 min, with brief mixing and
centrifugation after 3–4 min of incubation. After amplification at
39uC for 20 min, 2 ml of amplification product was diluted in
100 ml of PBST buffer, and 10 ml of diluted amplicon was dropped
on the sample pad of a HybriDetect lateral flow stripe (LFS)
(Milenia Biotec, Giessen, Germany). Strips were then placed into
tubes containing 100 ml of PBST buffer. The final result was read
visually after 5 min of incubation. A test was considered positive
when the detection line as well as the control line was visible. A test
was considered negative when only the control line was visible.
Real-time RT-RPA assay
Real-time RT-RPA assay was performed using the Twis-
tAmpTM exo RT kit according to the manufacturer’s instructions.
The TwistAmpTM exo RT kit contains an additional RT-enzyme
enabling the DNA amplification of RNA targets. Briefly, 37.7 ml of
rehydration solution were mixed with 2.1 ml of each primer
(10 mM) and 0.6 ml of the target-specific RPA exo probe (10 mM).
Then 5 ml of RNA template was added to the 42.5 ml master mix.
The template/master mix solution was added to the dry reagent
pellet and mixed by pipetting up and down. Finally, the reaction
was triggered by adding 3.5 ml of Mg(OAc)2 (280 mM) to the
47.5 ml reaction mix. The reaction tubes were mixed, centrifuged
and then placed into the ESE Quant Tube Scanner for real-time
monitoring of fluorescence. Reaction was performed at 39uC for
20 min, with brief mixing and centrifugation of reaction tubes
after 3–4 min of incubation. This reaction temperature was
determined optimal in terms of sensitivity. For data analysis, the
Tube Scanner requires to be connected to a computer installed
with the ESEQuant Tube Scanner software Version 1.0.
Threshold values were determined by slope validation, i.e. slope
(mV/min) values were compared in order to distinguish positive
results from negative results. Further development and standard-
ization of the method would allow using the device on its own with
a direct display of positive or negative results for each sample.
Analytical specificity of real-time and LFS RT-RPA
To test whether our assay is able to detect a wide variety of YFV
strains, we utilized a panel of 20 different YFV strains described in
Table 1. The analytical specificity was tested with a panel of 13
arboviruses and hemorrhagic fever viruses of which 9 are
flaviviruses genetically related to YFV (Table 2).
Analytical sensitivity of real-time and LFS RT-RPA
RT-RPA analytical sensitivity was evaluated by testing RNA
extracts from 10-fold serial dilutions of YFV preparations
comparatively to real-time RT-PCR used as the reference method.
RNA was extracted from the YFV Asibi strain and RNA
concentrations ranged from 26105 to 8 genome equivalent copies
per reaction (GC/rxn). Repeatability of the method was assessed
by testing each dilution 10 times with real-time RT-RPA and 5
times with LFS-RT-RPA.
Centrifugal microfluidic cartridge
Centrifugal microfluidic cartridges [19], termed GeneSlice
(HSG-IMIT, Lab on a Chip Design- and Foundry Service,
Freiburg, Germany), were used to demonstrate process automa-
tion of real-time RT-RPA in a small and portable processing
device, the ‘‘SONDE’’ player, that may be used in the field with
minimum manual interaction (Fig. 1B). The GeneSlice contains a
microfluidic channel network that allows to aliquot an initial
reaction mixture into 8 subvolumes by applying centrifugal forces.
Each subvolume is then transferred into a separated amplification
chamber (Fig. 1A) [20,21].
The reaction mixture was composed of 73 ml rehydration
solution, 4.2 ml forward/reverse primer (10 mM each), 1.2 ml
probe (10 mM), 7 ml of Mg(OAc)2 (280 mM) and 10 ml of the
DNA/RNA template. Three lyophilized pellets from the Twis-
tAmpTM exo RT kit were resuspended in the 90 ml-reaction
mixture. The reaction mixture is aliquoted into eight 10 ml
volumes and transferred into amplification chamber by centrifuge
force. Excess mixture is collected into a waste chamber. The
‘‘SONDE’’ player heats the samples at 41uC and RPA reaction is
initiated in each amplification chamber. The fluorescence signal
produced by the amplification is monitored for 20 minutes by the
integrated detection unit. Amplification results were analyzed
using IsoAmp Software (QIAGEN Lake Constance GmbH,
Stockach, Germany).
Field trial of real-time RT-RPA
Real-time RT-RPA assay combined with a magnetic bead-
based extraction method was tested under field conditions in
Senegal. Inactivated YFV virus and YFV RNA controls were
prepared in dry-stabilized format using DNAstable Blood and
RNAstable reagents (Biomatrica, San Diego, USA), respectively.
These controls were stored at ambient temperature until further
use in the field.
For the field trial of real-time RT-RPA, all reagents and
instruments required were packed and transported by car from
Dakar (14u439120N 17u289480W) to Mbour (14u259190N
16u579510W) at ambient temperature. At the Mbour city health
center, the RPA setup was deployed and RNA was extracted from
dry-stabilized virus controls using innuPrep MP basic kit.
Subsequently, the extracted RNAs were tested with real-time
RT-RPA for YFV. In order to reproduce field conditions where
no power supply is available, the Tube Scanner was powered by a
battery charged by solar panels.
Results
Primer and probe design for RPA
By analyzing the alignment of all available full genome
sequences of YFV, the conserved 59-non-coding region (NCR) of
the YFV genome was chosen for primer and probe design
(Table 3). The primer set YFV RF/RR efficiently amplified YFV
RNA in LFS RT-RPA and real-time RT-RPA assays.
Analytical specificity of real-time and LFS RT-RPA
The analytical specificity testing revealed that all the 20 different
YFV strains were detected by both LFS and real-time RT-RPA
assays. The testing results of the panel of 13 viruses other than
YFV showed no cross-reactions, as all results were negative for
both assays (Table 2). However, concerns with specificity were
encountered with the LFS RT-RPA assay, as a faint band was
observed in the negative controls when running time exceeded
5 minutes, thus potentially generating false-positive results.
Analytical sensitivity of real-time and LFS RT-RPA
The analytical sensitivity of RT-RPA assays was evaluated by
testing the RNA extracts from 10-fold serial dilutions of YFV
preparations and by comparing real-time RT-RPA and real-time
RT-PCR test results. The real-time RT-PCR showed linear results
for the quantification of RNA standards over a range of 10 to 106
genome copies. Real-time RT-PCR detected as low as 8 GC/rxn
while real-time and LFS RT-RPA assays could detect as low as 44
GC/rxn in YFV RNA extracts and 21 GC/rxn for the testing of
Rapid RNA Detection of Yellow Fever Virus
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YFV-spiked human plasma samples (Figure 2). The amplification
curves of the YFV RNA extracts from 10-fold serial dilutions are
shown in Figure 3-A for real-time RT-RPA results and Figure 3-B
for real-time RT-PCR results.
Testing of mosquito pools with real-time RT-RPA on the
Tube Scanner
Thirty-four samples of monospecific pools of wild-caught
mosquitoes collected from Kedougou, southern Senegal were
included in this study. The RNA extracts from these samples were
tested in parallel with real-time RT-PCR and RT-RPA. Fourteen
mosquito samples out of 34 (41.2%) resulted negative in real-time
RT-PCR and 20 were positive (58.8%) with Ct values ranging
from 24.65 to 35.51 (data not shown). Of the 20 samples detected
positive in real-time RT-PCR, 16 were tested positive by real-time
RT-RPA assay, providing a sensitivity of 80% (95% CI: 56.3% to
94.1%). Of the 14 samples tested negative in real-time RT-PCR,
all were also tested negative by real-time RT-RPA assay, providing
a specificity of 100% (95% CI: 76.7% to 100%). The overall
agreement between the two assays was 88.4% (30/34) (Table 4).
Testing of mosquito pools with real-time RT-RPA on the
microfluidic platform
Twenty-seven RNA samples of mosquito pools were included in
this part of the study. Thirteen mosquito samples out of 27 (48.1%)
had negative results in real-time RT-PCR and 14 were positive
(51.9%), with Ct values ranging from 27 to 35.5 (data not shown).
Of the 14 samples tested positive with real-time RT-PCR, 10 were
tested positive by real-time RT-RPA, providing a sensitivity of
71.4% (95%CI: 41.9% to 91.4%). All of the 13 samples that tested
negative in real-time RT-PCR were also tested negative by real-
time RT-RPA assay, providing a specificity of 100% (95% CI:
75% to 100%). The overall agreement between the two assays was
85.2% (23/27) (Table 4).
Figure 1. Centrifugal microfluidic platform. A: GeneSlice cartridge contains the microfluidic structure for aliquoting the reaction mix into eight
10 ml subvolumes; B: Prototype device for processing the GeneSlices (‘‘SONDE player’’) featuring defined rotation, acceleration and deceleration,
heating and fluorescence detection (QIAGEN Lake Constance GmbH, Stockach, Germany).
doi:10.1371/journal.pntd.0002730.g001
Table 3. List of primers and probe for the lateral-flow stripe and real-time RPA assay based on the YFV strain accession nu
NC00203.
Assay format Oligo name Sequence 59R39 Direction Position
Lateral-flow stripe
RT-RPA
YFV RF AAATCCTGTGTGCTAATTGAGGTGYATTGG sense 4 to 33
YFV RR-Bio Biotin- ACATDWTCTGGTCARTTCTCTGCTAATCGC antisense 93 to 122
YFV Rprobe nfo FAM-CTGCAAATCGAGTTGCTAGGCAATAAACAC[THF] TTTGGATT-AATTTTRATCGTT-Ph sense 35 to 86
Real-time RT-RPA YFV RF AAATCCTGKGTGCTAATTGAGGTGYATTGG sense 4 to 33
YFV RR ACATDWTCTGGTCARTTCTCTGCTAATCGC antisense 93 to 122
YFV Rprobe exo gCAAATCgAgTTgCTAggCAATAAACACATT[BHQdT]g[THF]A[FAMdT]TAATTTTRATCgTTC-Ph sense 37 to 87
FAM: 6-Carboxyfluorescein; THF: tetrahydrofuran; Ph: 39phosphate to block elongation; BHQ: black hole quencher.
doi:10.1371/journal.pntd.0002730.t003
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Field testing of real-time RT-RPA
The virus and RNA controls were stabilized with DNAstable
Blood and RNAstable reagents and tested in the laboratory using
real-time RT-PCR and real-time RT-RPA. These results were
compared to the testing results of the same amount of control
samples without stabilizer, stored at 220uC. Results were
comparable and proved the stabilization process to be effective.
The average cycle threshold (Ct) and time threshold (Tt) values for
all samples were 31.08 (SD = 0.74) and 5.5 (SD = 0.22), respec-
tively. When stabilized controls and non-stabilized controls at
220uC were tested on real-time RPA during the field trial, the
mean of Tt values of these samples was 5.3. These results are
comparable to the values detected previously in the laboratory,
indicating good reproducibility of the complete experimental
workflow in the field.
Discussion
In this study, we describe the development of a RT-RPA assay
for YFV detection which can be performed without complex
equipment in a basic laboratory setting, a rural health care center
or an outbreak field investigation. We designed a set of primers
and probe and developed a real-time methodology which enables
to detect down to 21 GC/rxn. This detection limit is slightly
higher than the 8 GC/rxn detected by real-time PCR [9].
Nonetheless, this level of sensitivity is sufficient to detect wild-type
YFV in natural infections or serious adverse events (SAEs)
following YFV immunization which produce viremia levels up to
108 PFU/ml [22–24].
Test results for spiked human plasma samples indicated that
serum does not affect significantly the assay sensitivity. Therefore,
we can assume that the test can be applied for laboratory case
confirmation of suspected YFV cases. However, there is further
need to validate intensively the assay using YF clinical samples
from various endemic countries and from patients at different
stages of the disease.
The LFS-RPA assay experienced specificity problems, as a faint
nonspecific band appeared in the negative controls when running
time exceeded 5 minutes. Such faint bands have not been
observed neither for the very low dilutions of YFV RNA nor
during testing of other viruses. Therefore, these false-positive
results are not due to contamination but rather to the clotting of
proteins or primers which could not bind to any template.
Unequivocal interpretation of LFS may be provided by an
Figure 2. Sensitivity testing of the real-time and LFS RT-RPA with YFV cell supernatant and human plasma spiked with YFV in
comparison with real-time RT-PCR results. Ct: cycle threshold; Tt: time threshold; Neg.: Negative; Pos.: Positive; Undet.: Undetermined.
doi:10.1371/journal.pntd.0002730.g002
Figure 3. Amplification plots of real-time measurements for extracted RNA from 10-fold serial dilutions of YFV; A: RT-PCR results;
B: RT-RPA results.
doi:10.1371/journal.pntd.0002730.g003
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ESEQuant Lateral Flow Reader (QIAGEN Lake Constance
GmbH, Stockach, Germany). However, at this point, we
recommend particular caution during LFS operation and inter-
pretation and further optimization of the assay before use under
field conditions.
Real-time RT-RPA results demonstrated an optimal specificity.
Testing results of the mosquito pools demonstrated an analytical
specificity of 100% on both the Tube Scanner and the microfluidic
GeneSlice cartridge. Real-time RT-RPA on the microfluidic
GeneSlice cartridge showed a statistically similar sensitivity (71.4%
and 80% respectively) as the confidence intervals of both sensitivity
values overlap. The lower sensitivity value of the GeneSlice
method might be due to the complexity of the microfluidic unit
operations which comprises release of liquid reagents, reconstitu-
tion of lyophilized reagents, aliquoting the sample into eight
independent reaction cavities and mixing of reagents with the
RNA samples. Nevertheless, the performance of the GeneSlice is
satisfying, and no cross-contamination between wells was ob-
served. Moreover, this semi-automated and downscaled system
leads to a significant reduction in costs, manual work and waste,
making it an attractive method for point-of-care applications such
as the screening for hemorrhagic fevers in Africa. However, the
real-time RT-RPA on the Tube Scanner was used for further
evaluation including in field conditions because of its higher
sensitivity.
During the field study, real-time RT-RPA has demonstrated
similar performance to that during previous testing under
laboratory conditions. Based on our results, the assay proves to
have great potential as a point-of-care molecular diagnostic
method for various reasons: all reagents are lyophilized with the
main RPA reagents provided in a single dried pellet, which
simplifies assay preparation and allows long-term storage at room
temperature; amplification is performed at constant temperature;
ESEQuant Tube Scanner device is significantly lighter, smaller
and cheaper than all other available mobile PCR cyclers or
turbidimeter devices for LAMP assays; the assay has a low energy
consumption; reaction times are short and the system is simple,
robust and portable.
The cost is approximately 4 euros per test for real-time RPA
and 5 euros per test for real-time RT-PCR in lyophilized form. At
this stage, costs per sample for both techniques are comparable.
However RT-RPA is a newly developed technique and prices are
likely to decrease in the future while availability and throughput
will increase. Furthermore, the detection device for real-time RPA
is approximately 10 times cheaper than a real-time PCR machine.
An external quality assessment study on diagnostic methods for
YFV infections launched in 2011 revealed that the main weakness
observed for molecular methods was the inability of some assays to
detect the YFV genome of wild-type strains, whereas the vaccine
strain was always detected [25]. This specificity problem has not
been observed for the YFV RT-RPA assay, as all YFV strains were
detected. Furthermore, our assay revealed no cross-reactions with
other closely related viruses.
Recently, another isothermal amplification method for YFV
detection was developed based on reverse transcription loop-
mediated isothermal amplification (RT-LAMP) technology [14].
In contrast to RPA, LAMP requires a larger set of six primers, a
higher temperature (62uC) and a longer run time. Sensitivity is not
comparable, as results of RT-LAMP were expressed as PFU
instead of GC detected, but RT-LAMP usually presents equal or
lower sensitivity than RPA [26,27]. In fact LAMP uses nonspecific
intercalating fluorophores for detection while RPA uses specific
detection probes.
In summary, we have developed a very rapid and sensitive
isothermal RPA assay in real-time and lateral-flow stripe format
for the detection of YFV. Both of these assays can be easily applied
in low-resource settings as an alternative to traditional laboratory-
based molecular diagnostic assays. However, the LFS format
needs further optimization to exclude all risks of false-positive
results. The real-time RT-RPA assay, using the transportable
Tube Scanner device combined with the RNA extraction method
based on magnetic beads, and the use of lyophilized reagents
which can be stored at ambient temperature allowed us to apply
our RPA assay under field conditions in Senegal with performance
similar to that of cutting-edge laboratory settings.
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Table 4. Performance of the real-time RT-RPA assay using the Tube Scanner or the GeneSlice cartridge in comparison to the
reference method, real-time RT-PCR, for detecting YFV in mosquito pools.
Real-time RT-PCR Performance characteristics (%)
Positive Negative Sensitivity Specificity PPV NPV
RT-RPA on
Tubescanner
Positive 16 0 80% 100% 100% 77.8%
Negative 4 14
Total (n = 34) 20 14
RT-RPA on Positive 10 0 71.4% 100% 100% 76.5%
GeneSlice Negative 4 13
Total (n = 27) 14 13
PPV: positive predictive value; NPV: negative predictive value.
doi:10.1371/journal.pntd.0002730.t004
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